Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2013

01-10-2013 | Review Article

Skin involvement in ANCA-associated vasculitis

Author: Ko-Ron Chen

Published in: Clinical and Experimental Nephrology | Issue 5/2013

Login to get access

Abstract

The skin is a common target organ in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Skin lesions may present as the initial manifestation or as the associated cutaneous manifestations in ANCA-associated vasculitis. Visually assessing the cutaneous manifestations and performing a biopsy of skin lesions to facilitate histopathologic confirmation are highly valuable diagnostically. Vasculitis (which affects dermal small vessels and subcutaneous muscular vessels) and nonvasculitic inflammation cause various types of skin lesions. The coexistence of different levels of vasculitis and nonvasculitis can occur in one or in several lesions or on different occasions. These puzzling clinical and histopathologic features may be closely related to the disease activity. Understanding the complicated clinical and histopathologic spectrum of skin lesions will contribute to the early diagnosis of ANCA-associated vasculitis with cutaneous complications.
Literature
1.
go back to reference Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol. 2008;9:71–92.PubMedCrossRef Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol. 2008;9:71–92.PubMedCrossRef
3.
go back to reference Guillevin L, Cohen P, Gayraud M, Lhote F, et al. Churg Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78:26–37.CrossRef Guillevin L, Cohen P, Gayraud M, Lhote F, et al. Churg Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78:26–37.CrossRef
4.
go back to reference Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421–30.PubMedCrossRef Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421–30.PubMedCrossRef
5.
go back to reference Duna GF, Galperin C, Hoffman GS. Wegener’s granulomatosis. Rheum Dis Clin North Am. 1995;21:949–86.PubMed Duna GF, Galperin C, Hoffman GS. Wegener’s granulomatosis. Rheum Dis Clin North Am. 1995;21:949–86.PubMed
6.
go back to reference Chen KR, Sakamoto M, Ikemoto K, et al. Granulomatous arteritis in cutaneous lesions of Churg–Strauss syndrome. J Cutan Pathol. 2007;34:330–7.PubMedCrossRef Chen KR, Sakamoto M, Ikemoto K, et al. Granulomatous arteritis in cutaneous lesions of Churg–Strauss syndrome. J Cutan Pathol. 2007;34:330–7.PubMedCrossRef
7.
go back to reference Chen KR. Histopathology of cutaneous vasculitis. In: Amezcua-Guerra LM, editor. Advances in the diagnosis and treatment of vasculitis; 2011. p. 19–56 (ISBN: 978-953-307-786-4). Chen KR. Histopathology of cutaneous vasculitis. In: Amezcua-Guerra LM, editor. Advances in the diagnosis and treatment of vasculitis; 2011. p. 19–56 (ISBN: 978-953-307-786-4).
8.
go back to reference Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthritis Rheum. 2005;52:2926–35.PubMedCrossRef Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthritis Rheum. 2005;52:2926–35.PubMedCrossRef
9.
10.
go back to reference Ishibashi M, Kudo S, Yamamoto K, et al. Churg–Strauss syndrome with coexistence of eosinophilic vasculitis, granulomatous phlebitis and granulomatous dermatitis in bullous pemphigoid-like blisters. J Cutan Pathol. 2011;38:290–4.PubMedCrossRef Ishibashi M, Kudo S, Yamamoto K, et al. Churg–Strauss syndrome with coexistence of eosinophilic vasculitis, granulomatous phlebitis and granulomatous dermatitis in bullous pemphigoid-like blisters. J Cutan Pathol. 2011;38:290–4.PubMedCrossRef
11.
go back to reference Wilmonth GJ, Perniciaro C. Cutaneous extravascular necrotizing granuloma (Winkelmann granuloma): confirmation of the association with systemic disease. J Am Acad Dermatol. 1996;34:753–9.CrossRef Wilmonth GJ, Perniciaro C. Cutaneous extravascular necrotizing granuloma (Winkelmann granuloma): confirmation of the association with systemic disease. J Am Acad Dermatol. 1996;34:753–9.CrossRef
12.
go back to reference Daoud MS, Gibson LE, DeRemee RA, et al. Cutaneous Wegener’s granulomatosis: clinical, histopathologic and immunopathologic features of thirty patients. J Am Acad Dermatol. 1994;31:605–12.PubMedCrossRef Daoud MS, Gibson LE, DeRemee RA, et al. Cutaneous Wegener’s granulomatosis: clinical, histopathologic and immunopathologic features of thirty patients. J Am Acad Dermatol. 1994;31:605–12.PubMedCrossRef
13.
go back to reference Reed WB, Jensen AK, Konwaler BE, et al. The cutaneous manifestation in Wegener’s granulomatosis. Acta Derm Venereol (Stockh). 1963;43:250–64. Reed WB, Jensen AK, Konwaler BE, et al. The cutaneous manifestation in Wegener’s granulomatosis. Acta Derm Venereol (Stockh). 1963;43:250–64.
Metadata
Title
Skin involvement in ANCA-associated vasculitis
Author
Ko-Ron Chen
Publication date
01-10-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0736-x

Other articles of this Issue 5/2013

Clinical and Experimental Nephrology 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine